UNSPSC 51281624: Streptomycin

This classification denotes an aminoglycoside antibiotic with the molecular formula C21H39N7O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y45QSO73OB, chemically known as 2,4-diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-o-(2-deoxy-2-methylamino-alpha-l-glucopyranosyl)-3-c-formyl-beta-l-lyxopentanofuranoside but generally known as streptomycin, which bears US NIH Compound Identifier 5999.

UNSPSC 51281624 Streptomycin is a Commodity code for a specific pharmaceutical active ingredient; however, the recent state and local opportunities tagged under it do not reflect streptomycin procurement. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets, and Seminole County, Florida released an IFB in June 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually. State and local health agencies use piggyback purchasing through established pharmaceutical consortiums to supply essential drugs and emergency-response medications in bulk, leveraging existing master agreements to reduce procurement cycle time and achieve volume pricing. The issuing bodies soliciting under this code are state health departments and county health authorities managing public health stockpiles and community health initiatives.

The recent activity concentrates in Florida and Illinois. The Illinois Department of Public Health's award to Chartwell Rx LLC closed on September 11, 2026, under a 12-month initial term with renewal options, while Seminole County's IFB for naloxone and deactivation systems carried a July 26, 2023 response deadline and requires quarterly deliveries to the Seminole County Community Health Building in Sanford. The code shows limited recent activity specifically for streptomycin; the tagged opportunities represent antibiotic and emergency-response pharmaceutical procurement more broadly, suggesting potential classification drift or consortial purchasing that aggregates multiple drug categories under a single notice.